Press releases
- Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
- Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
- Incyte to Report First Quarter Financial Results
- Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
- Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
- Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
- New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
- Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
- Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
More ▼
Key statistics
As of last trade Incyte Corp (ICY:STU) traded at 48.74, 3.18% above its 52-week low of 47.24, set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 48.99 |
---|---|
High | 48.99 |
Low | 47.53 |
Bid | 48.50 |
Offer | 48.87 |
Previous close | 49.08 |
Average volume | 6.25 |
---|---|
Shares outstanding | 224.53m |
Free float | 220.96m |
P/E (TTM) | 19.57 |
Market cap | 11.62bn USD |
EPS (TTM) | 2.64 USD |
Data delayed at least 15 minutes, as of Apr 30 2024.
More ▼